MRK

MRK's growth momentum faces patent and competitive risks as Keytruda demand and new launches support growth.

Merck's Keytruda and Gardasil sales rise in Q3, but inventory reversals, slowing demand and looming competition could challenge growth.

Dow Dogs remain pricey with thin dividends, but 21 of 30 are ‘safer' due to robust free cash flow supporting payouts. Analyst targets project 16.96% to 60.26% net gains for top-ten Dow Dogs by November 2027, though risks and volatility are elevated. None of the top ten Dow Dogs currently meet the ideal dividend-to-price ratio; only Nike achieves 'IDEAL' status but with negative returns and a weak safety margin.

Three of the biggest names in pharma and vaccines are trading against their own headlines. Moderna (NASDAQ:MRNA | MRNA Price Prediction) stock is at $231.

Merck just posted its sixth straight earnings beat and its CEO is targeting $70 billion in mid-2030s revenue, yet the stock carries a looming patent cliff that could reshape everything.

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MERCK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of ENHANCE-3 (NCT07874815), a Phase 3 randomized clinical trial evaluating OHTUVAYRE (ensifentrine) for the prevention of chronic obstructive pulmonary disease (COPD) exacerbations in adult patients receiving standard of care (SOC) with a history of exacerbations. Recruitment of the ENHANCE-3 trial has begun, and the first patients are now enrolling in the Unite.

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--New data include Phase 3 subgroup analyses and patient-reported outcomes of investigational once-weekly oral combination of ISL/LEN.

Moderna co-founder and board chairman Noubar Afeyan discusses the biotech company's melanoma vaccine trial results and efforts to secure FDA approval on 'The Claman Countdown.'

Dividends keep paying whether you sell or not, and four healthcare giants quietly generate serious retirement income while you sleep. But not every yield here is as safe as it looks.

A strong third quarter has made Regeneron Pharmaceuticals (NASDAQ:REGN | REGN Price Prediction) a standout healthcare gainer on a day when tech stocks are selling off. In morning trading, Regeneron stock has climbed to $919.58, up 12%.